Skip to Content

Palmeux prolonged-release suspensions for injection in prefilled syringe, 50 mg, 75 mg, 100 mg, and 150 mg strengths, PA1142/040/002-005, Recall, all batches

02/01/2026
Medicines for human use Recall

We wish to advise you that all in-date batches of Palmeux prolonged-release suspensions for injection in prefilled syringe, 50 mg, 75 mg, 100 mg, and 150 mg strengths are being recalled as a precautionary measure with immediate effect.

This recall is going to pharmacy level.

This recall is a precautionary measure due to GMP deficiencies identified at the manufacturing site.

The recall letters, dated 24th December 2025, can be downloaded in the Documents section at the bottom of this webpage. 

Product information

Product name
Palmeux 50 mg prolonged-release suspension for injection in prefilled syringe
Palmeux 75 mg prolonged-release suspension for injection in prefilled syringe
Palmeux 100 mg prolonged-release suspension for injection in prefilled syringe
Palmeux 150 mg prolonged-release suspension for injection in prefilled syringe
Authorisation holder
Amdipharm Limited (trading as ADVANZ PHARMA Operations)
Authorisation number

PA1142/040/002

PA1142/040/003

PA1142/040/004

PA1142/040/005

Serial or batch number and expiry date
All in-date batches
Human or veterinary medicine
Human medicine
Target audience
Wholesalers and pharmacies
Recall level
Pharmacy level

Actions to be taken

Information for Pharmacists

Pharmacists are requested to perform the following actions:

  1. Please immediately quarantine any units of these products which you have in your possession. For hospital pharmacies, this includes units at wards, clinics and any other relevant locations within the hospital.
  2. If you have supplied these products to any other pharmacy, clinic or other such healthcare establishment, please forward a copy of the recall letter (in the Documents section at the bottom of this page) to them, requesting that they immediately quarantine and return any unused units back to you.
  3. Return all quarantined units to your wholesaler.

Information for Wholesalers

Wholesalers are requested to perform the following actions:

  1. Immediately identify and quarantine any units of these products which you have in your facility or are returned to you by your customers.
  2. If you have supplied these products to any other wholesaler(s), please forward a copy of the recall letter (in the Documents section at the bottom of this page) to those wholesalers, requesting that they immediately quarantine any unsold quantities of these products and return those back to you.
  3. Return all quarantined units to your supplier. 

Information for patients and public

No action is required by patients and public. If you have any of these products in your posession and you have any queries, please contact your pharmacist.

 

Documents

Opens in new window Palmeux_wholesale recall letter PDF : 2.57MB | 02/01/2026 Opens in new window Palmeux_pharmacy recall letter PDF : 2.57MB | 02/01/2026